Abstract 1512P
Background
Life expectancy has currently increased and pancreaticoduodenectomy (PD) is being performed more frequently on elderly patients in Japan. Surgical treatment for pancreatic ductal adenocarcinoma (PDAC) in patients over 80 years old is increasingly accepted, although it may lead to a decline in quality of life after surgery. Currently, there are no definitive indications for PD in octogenarians. This study aims to examine the surgical indications for PD in this age group, focusing on clinical background and perioperative and postoperative outcomes.
Methods
This retrospective analysis included patients with PDAC who underwent PD between 2012 and 2022. Patients aged ≥80 years were categorized as the Elderly (E) group, while those <80 years were classified as the Non-elderly (N) group. We compared clinical backgrounds, perioperative, and postoperative outcomes between the groups.
Results
PD was performed on 147 patients with PDAC. The median age was 71 years (range 45-85). Twenty-two patients (15.0%) were in the E group and 125 (85.0%) in the N group. The median Charlson comorbidity index (CCI) was significantly higher in the E group (6, range 5-10) compared to the N group (4, range 1-11; p
Conclusions
PD could be safely performed in elderly patients in good physical condition, with the survival benefit of PD for PDAC appearing as promising in elderly patients as in non-elderly patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Keio University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1435P - Immunomodulatory effects and improved survival of PG2 plus preoperative chemoradiotherapy in patients with locally advanced esophageal cancer
Presenter: Lai-Man Mok
Session: Poster session 18
1436P - Better overall survival of male versus female patients with advanced gastric adenocarcinoma
Presenter: Minggui Pan
Session: Poster session 18
1437P - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Presenter: Marcia Cruz-Correa
Session: Poster session 18
1438P - First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW
Presenter: Yoon-Koo Kang
Session: Poster session 18
1439P - ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study
Presenter: John Strickler
Session: Poster session 18
1440P - Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase II trial
Presenter: Chao Cheng
Session: Poster session 18
1441P - Clinical application of a machine learning-based pathomics signature for predicting lymph node metastasis in early gastric cancer
Presenter: Weiyao Li
Session: Poster session 18
1442P - Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy
Presenter: Hiroki Osumi
Session: Poster session 18
1444P - Nature trumps nurture: Squamous cell carcinoma remains the leading cause of esophageal cancer in Asian-Americans
Presenter: Shubham Gulati
Session: Poster session 18